Hodgkin Lymphoma

Oncology·MeSH: Lymphoma

Prevalence

56.0 / 100K

Incidence

19.6 / 100K/yr

162 drugs in development·54 companies·29 clinical trials

Drug Pipeline by Phase

Approved(4)

Drug	Company
belrapzo	EAGLE PHARMACEUTICALS, INC. (EGRX)
doxorubicin	Amneal Pharmaceuticals, Inc. (AMRX)
methotrexate	ELITE PHARMACEUTICALS INC /NV/ (ELTP)
ZYNLONTA (loncastuximab tesirine)	ADC Therapeutics SA (ADCT)

Phase 3(52)

Drug	Company
aNK	ImmunityBio, Inc. (IBRX)
AZD0486 IV	ASTRAZENECA PLC (AZN)
AZD4512	ASTRAZENECA PLC (AZN)
bendamustine	BeOne Medicines Ltd. (ONC)
bendamustine	BeOne Medicines Ltd. (ONC)
bendamustine	GH Research PLC (GHRS)
Bendamustine	BeOne Medicines Ltd. (ONC)
Bendamustine Hydrochloride	Filana Therapeutics Inc. (FLNA)
bgb-21447	BeOne Medicines Ltd. (ONC)
bleomycin	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
bleomycin	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
Bleomycin	Structure Therapeutics Inc. (GPCR)
Bleomycin Sulfate	Cosmos Health Inc. (COSM)
Bleomycin Sulfate	PTC THERAPEUTICS, INC. (PTCT)
brentuximab vedotin	Merck & Co., Inc. (MRK)
Brentuximab vedotin	Structure Therapeutics Inc. (GPCR)
Brentuximab Vedotin	Cosmos Health Inc. (COSM)
Brentuximab Vedotin	AXIM BIOTECHNOLOGIES, INC. (AXIM)
chemotherapy agents	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
Dacarbazine	Cosmos Health Inc. (COSM)
Dacarbazine	Structure Therapeutics Inc. (GPCR)
Dacarbazine	AXIM BIOTECHNOLOGIES, INC. (AXIM)
Etoposide	Cosmos Health Inc. (COSM)
Etoposide	AXIM BIOTECHNOLOGIES, INC. (AXIM)
Etoposide	PTC THERAPEUTICS, INC. (PTCT)
Etoposide Phosphate	AXIM BIOTECHNOLOGIES, INC. (AXIM)
Etoposide Phosphate	PTC THERAPEUTICS, INC. (PTCT)
Etoposide Phosphate	Cosmos Health Inc. (COSM)
filgrastim	GH Research PLC (GHRS)
Fludarabine Injection	Filana Therapeutics Inc. (FLNA)
gamunex-c	Grifols S.A. (GRFS)
Haematopoietic growth factor	PTC THERAPEUTICS, INC. (PTCT)
hmpl-523	HUTCHMED (China) Limited (HCM)
hmpl-523	HUTCHMED (China) Ltd (HMDCF)
obinutuzumab	BeOne Medicines Ltd. (ONC)
Obinutuzumab	BeOne Medicines Ltd. (ONC)
Procarbazine Hydrochloride	Cosmos Health Inc. (COSM)
Procarbazine Hydrochloride	Filana Therapeutics Inc. (FLNA)
Procarbazine Hydrochloride	PTC THERAPEUTICS, INC. (PTCT)
rondecabtagene autoleucel	Lyell Immunopharma, Inc. (LYEL)
Surovatamig	ASTRAZENECA PLC (AZN)
tak-007	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
tisagenlecleucel after optional bridging	NOVARTIS AG (NVSEF)
tisagenlecleucel after optional bridging	Novartis AG (NVS)
vinblastine	GH Research PLC (GHRS)
vinblastine	Merck & Co., Inc. (MRK)
Vinblastine	Structure Therapeutics Inc. (GPCR)
Vinblastine Sulfate	Cosmos Health Inc. (COSM)
Vinblastine Sulfate	PTC THERAPEUTICS, INC. (PTCT)
vincristine	Merck & Co., Inc. (MRK)
Vincristine Sulfate	PTC THERAPEUTICS, INC. (PTCT)
Vincristine Sulfate	Cosmos Health Inc. (COSM)

Phase 2(42)

Drug	Company
azacitadine	AbbVie Inc. (ABBV)
bleomycin	Merck & Co., Inc. (MRK)
bleomycin	Merus N.V. (MRUS)
bleomycin	GH Research PLC (GHRS)
Bleomycin	FATE THERAPEUTICS INC (FATE)
brentuximab vedotin	GH Research PLC (GHRS)
brentuximab vedotin	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
Brentuximab Vedotin	UNITED THERAPEUTICS Corp (UTHR)
Brentuximab Vedotin	FATE THERAPEUTICS INC (FATE)
CAR T-cells	Filana Therapeutics Inc. (FLNA)
CAR T-cells	ADC Therapeutics SA (ADCT)
cc-99282	Genmab A/S (GMAB)
cc-99282	GENMAB A/S (GNMSF)
CD19 t-haNK- IV Administration	ImmunityBio, Inc. (IBRX)
CLLS52	Cellectis S.A. (CLLS)
cnct19	CASI Pharmaceuticals, Inc (DE) (CASI)
dacarbazine	Merck & Co., Inc. (MRK)
Dacarbazine	UNITED THERAPEUTICS Corp (UTHR)
dtic	GH Research PLC (GHRS)
DTIC	FATE THERAPEUTICS INC (FATE)
Enfortumab vedotin	UNITED THERAPEUTICS Corp (UTHR)
Etoposide	ADC Therapeutics SA (ADCT)
Etoposide	Merck & Co., Inc. (MRK)
Etoposide	FATE THERAPEUTICS INC (FATE)
Etoposide Phosphate	ADC Therapeutics SA (ADCT)
Filgrastim	FATE THERAPEUTICS INC (FATE)
g100	IMMUNE DESIGN CORP. (IMDZ)
Ibrutinib	ENANTA PHARMACEUTICALS INC (ENTA)
Ifosfamide	ADC Therapeutics SA (ADCT)
Ifosfamide	ENANTA PHARMACEUTICALS INC (ENTA)
iph6501	Innate Pharma S.A. (IPHA)
Loncastuximab tesirine	Filana Therapeutics Inc. (FLNA)
Mivavotinib (CB-659, formerly TAK-659)	Calithera Biosciences, Inc. (CALA)
mt-601	Marker Therapeutics, Inc. (MRKR)
Odronextamab	ENANTA PHARMACEUTICALS INC (ENTA)
Odronextamab	Filana Therapeutics Inc. (FLNA)
Odronextamab	ADC Therapeutics SA (ADCT)
polatuzumab vedotin	Genmab A/S (GMAB)
polatuzumab vedotin	GENMAB A/S (GNMSF)
UCART20x22	Cellectis S.A. (CLLS)
Vinblastine	FATE THERAPEUTICS INC (FATE)
Vinblastine	UNITED THERAPEUTICS Corp (UTHR)

Phase 1(31)

Drug	Company
ARV-393	ARVINAS, INC. (ARVN)
ATA3219	Atara Biotherapeutics, Inc. (ATRA)
Autologous BAFFR-targeting CAR T Cells	Filana Therapeutics Inc. (FLNA)
Bendamustine	Filana Therapeutics Inc. (FLNA)
Bleomycin	PTC THERAPEUTICS, INC. (PTCT)
Bleomycin	ENANTA PHARMACEUTICALS INC (ENTA)
cc-122	BRISTOL MYERS SQUIBB CO (BMY)
cd19 t-hank	ImmunityBio, Inc. (IBRX)
CD19-CD34t metabolically programmed CAR transduced T-cells	Filana Therapeutics Inc. (FLNA)
CTX-8371	Compass Therapeutics, Inc. (CMPX)
duet-01	Scopus BioPharma Inc. (SCPS)
epcoritamab	Genmab A/S (GMAB)
epcoritamab	Genmab A/S (GMAB)
jcar017	Juno Therapeutics, Inc. (JUNO)
jnj-90009530	GH Research PLC (GHRS)
KRAS TCR-Transduced PBL	Filana Therapeutics Inc. (FLNA)
Loncastuximab tesirine	ADC Therapeutics SA (ADCT)
mb-106	MUSTANG BIO, INC. (MBIO)
mb-cart2019.1 dose level 1	CELLULAR BIOMEDICINE GROUP, INC. (CMBG)
mb-cart2019.1 dose level 2	CELLULAR BIOMEDICINE GROUP, INC. (CMBG)
mosunetuzumab	ADC Therapeutics SA (ADCT)
obinutuzumab	ADC Therapeutics SA (ADCT)
odronextamab	REGENERON PHARMACEUTICALS, INC. (REGN)
pic1	PRECISION BIOSCIENCES INC (DTIL)
pit565	Novartis AG (NVS)
pit565	Novartis AG (NVS)
polatuzumab vedotin	ADC Therapeutics SA (ADCT)
sar448501	Sanofi (SNY)
sc291	Sana Biotechnology, Inc. (SANA)
Veliparib	Filana Therapeutics Inc. (FLNA)
vispa-cel	Caribou Biosciences, Inc. (CRBU)

Preclinical(1)

Drug	Company
zandelisib	Lite Strategy, Inc. (LITS)

Unknown(1)

Drug	Company
Bleomycin Sulfate	ENANTA PHARMACEUTICALS INC (ENTA)

Phase 1/Phase 2(17)

Drug	Company
ab-101	Artiva Biotherapeutics, Inc. (ARTV)
anti-cd19 car t-cells	GH Research PLC (GHRS)
AUTO4	Autolus Therapeutics plc (AUTL)
bendamustine	Artiva Biotherapeutics, Inc. (ARTV)
cho-h01	CHINA PHARMA HOLDINGS, INC. (CPHI)
cho-h01 at rp2d	CHINA PHARMA HOLDINGS, INC. (CPHI)
fludarabine	Lyell Immunopharma, Inc. (LYEL)
fludarabine	Artiva Biotherapeutics, Inc. (ARTV)
gen3017	GENMAB A/S (GNMSF)
gen3017	Genmab A/S (GMAB)
glpg5101	Galapagos NV (GLPG)
GLPG5101	Galapagos NV (GLPG)
hem101	GH Research PLC (GHRS)
interleukin-2	Artiva Biotherapeutics, Inc. (ARTV)
iph6501	Innate Pharma SA (IPHYF)
lyl314	Lyell Immunopharma, Inc. (LYEL)
Mosunetuzumab	BRISTOL MYERS SQUIBB CO (BMY)

Phase 4(14)

Drug	Company
anti-vascular endothelial growth factor	GH Research PLC (GHRS)
BMS-986458	BRISTOL MYERS SQUIBB CO (BMY)
brentuximab vedotin	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
Brentuximab Vedotin	Merus N.V. (MRUS)
Brentuximab Vedotin	PTC THERAPEUTICS, INC. (PTCT)
Dacarbazine	Merus N.V. (MRUS)
Daunorubicin Hydrochloride	Filana Therapeutics Inc. (FLNA)
Ponatinib Hydrochloride	Filana Therapeutics Inc. (FLNA)
vinblastine	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
vinblastine	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
Vinblastine	Merus N.V. (MRUS)
Vinblastine	PTC THERAPEUTICS, INC. (PTCT)
Vinblastine	ENANTA PHARMACEUTICALS INC (ENTA)
Zanubrutinib	BeOne Medicines Ltd. (ONC)

Compare drugs

belrapzo vs doxorubicin belrapzo vs methotrexate belrapzo vs ZYNLONTA (loncastuximab tesirine)

Frequently asked questions

How many drugs are in development for Hodgkin Lymphoma?

BioSniper tracks 162 drugs in development for Hodgkin Lymphoma across 54 companies.

How many clinical trials target Hodgkin Lymphoma?

There are 29 clinical trials targeting Hodgkin Lymphoma tracked by BioSniper.

What is the prevalence of Hodgkin Lymphoma?

The estimated prevalence of Hodgkin Lymphoma is approximately 56.0 per 100,000 population.

Deep-dive into Hodgkin Lymphoma

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis